RVL Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RVL Pharmaceuticals generated cash of -$37,810,000, which is more than the previous year. Cash used in financing activities reached the amount of $41,783,000 last year. Net change in cash is therefore $4,099,000.
Cash Flow
| 2016 | -44.79M | -453.46M | 420.51M |
|---|---|---|---|
| 2017 | 57.83M | -19.39M | -23.31M |
| 2018 | 37.55M | -4.13M | 3.60M |
| 2019 | 33.56M | -4.02M | -4.69M |
| 2020 | 17.59M | -3.08M | 3.68M |
| 2021 | -54.73M | 116.45M | -135.33M |
| 2022 | -37.81M | 126K | 41.78M |
RVLP Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 40.44M | 114.05M | 95.86M | 70.83M | 34.74M | 19.55M | 97.61M |
Operating activities | |||||||
Net income | -51.69M | -64.92M | -79.58M | -270.90M | -109.68M | -45.15M | -41.82M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 375K | 8.17M | 21.02M | 57.01M | 81.57M | 46.45M | 23.58M |
Stock-based compensation expense | 4.07M | 7.59M | 4.92M | 4.93M | 1.96M | 0 | 0 |
| Deferred income tax benefit | 4.07M | 7.59M | 4.92M | 4.93M | 1.96M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -898K | 7.10M | 17.49M | 12.67M | -17.04M | 5.26M | -12.52M |
Inventories | 54K | 2.59M | 3.37M | 3.07M | -7.43M | 2.89M | 12.56M |
Accounts payable | -1.37M | -134K | -1.72M | -16.37M | -11.32M | 588.23K | -14.38M |
Cash generated by operating activities | -37.81M | -54.73M | 17.59M | 33.56M | 37.55M | 57.83M | -44.79M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -752K | -1.78M | -3.13M | -4.03M | -4.14M | -6.89M | -15.93M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | -321M |
Cash generated by investing activities | 126K | 116.45M | -3.08M | -4.02M | -4.13M | -19.39M | -453.46M |
Financing activities | |||||||
Common Stock Issued | 23.63M | 32.41M | 62.44M | 0 | 58.08M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | -23.30M |
Repurchases of common stock | 0 | 0 | -8.10M | -2.78M | 0 | 0 | 0 |
Repayments of term debt | 0 | -222.30M | -50.12M | 0 | -57.22M | 0 | -4.26M |
Cash used in financing activities | 41.78M | -135.33M | 3.68M | -4.69M | 3.60M | -23.31M | 420.51M |
Net Change In Cash | 4.09M | -73.60M | 18.18M | 25.03M | 36.09M | 15.18M | -78.05M |
Cash at end of period | 44.54M | 40.44M | 114.05M | 95.86M | 70.83M | 34.74M | 19.55M |
| Data source | Data source | Data source | Data source | Data source |